RVPH - Pangali EV/EBITDA Reviva Pharmaceuticals Holdings, Inc.

The share price retrospective for Reviva Pharmaceuticals (RVPH) on the GURU.Markets platform demonstrates an EV/EBITDA of 0.00. The company is currently preparing to launch an innovative neuroleptic as it finalizes key tests. The business relies on the development of Brilaroxazine, which treats psychosis without weight-gain side effects. This sector is considered a safe haven, as the demand for psychiatric care is independent of market cycles, while success depends on FDA verdicts.

To build a defensive portfolio, fundamental screening requires an analysis of EV/EBITDA, which compares the total enterprise value (market capitalization and net debt) with operating profit before depreciation and amortization. In the case of Reviva Pharmaceuticals (RVPH), which is seeking a strategic partner for drug commercialization, the company's trend EV/EBITDA level reflects the value of its assets relative to their current efficiency during the completion of clinical trials.